Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection
2015
The group author, SECOND-LINE, was omitted from the author byline and should be listed as the fifteenth author. Please see the full list of contributing authors, as well as their full authorship contributions in the Acknowledgements section of the published article.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
18
References
54
Citations
NaN
KQI